Talis conducted a comprehensive in silico assessment comparing the Omicron (B1.1.529) variant published sequences from the GISAID database to its Talis One COVID-19 Test System. The bioinformatics analysis concluded that the Talis One COVID-19 molecular nucleic acid amplification test (NAAT) continues to be able to identify positive cases of COVID-19 caused by Omicron.
Like all viruses, SARS-CoV-2 continues to mutate. In anticipation of this fact, our scientists developed a test with a dual-gene target to ensure accurate results even in the case where one of the targets may become impacted by a mutation. The Omicron variant has been found to show multiple mutations, with a majority occurring on the spike (S) protein. Talis’ molecular NAAT does not rely on the S gene to detect the virus but rather focuses on two other targets: the N and Orf1a/b genes. Individually, >99% of the published Omicron sequences as of December 1, 2021 are a perfect match to both of the Talis primer regions, while across both targets 100% of the sequences match at least one primer set.
The robust multiple target test design helps to ensure that clinicians, researchers and public health officials have an effective tool for COVID-19 testing-even as the genetic makeup of the virus evolves.
Talis will continue surveillance of emerging SARS-CoV-2 variants of concern/interest (VOC/I) by assessing reactivity against genome sequence databases.
To date, Talis has performed assessments looking at the following variants
- Alpha (B.1.1.7)
- Beta (B.1.351)
- Delta (B.1.617.2)
- Epsilon (B.1.427 and B.1.429)
- Eta (B.1.525)
- Iota (B.1.525)
- Gamma (P.1)
- Zeta (P.2)
- Omicron (B.1.1.529)
- Data on file with Talis Biomedical. GISAID Database accessed December 1, 2021.